CSS LLC’s Arcturus Therapeutics ARCT Stock Holding History

CSS LLC’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-22,610	Closed	-$934K	–	1072
2021 Q1	$934K	Buy	22,610 +8,029	+55%	+$479K	0.04%	413
2020 Q4	$633K	Buy	+14,581	New	+$988K	0.02%	412

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

CSS LLC's ARCT Position: Q2 2021 in Review

CSS LLC sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 22,610 shares — an estimated $934K sold.

CSS LLC first reported a position in ARCT in Q4 2020 and held it in 2 quarters. The position peaked at $934K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

CSS LLC reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
CSS LLC sold 22,610 Arcturus Therapeutics shares in Q2 2021, an estimated $934K.
CSS LLC first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 2 quarters.
CSS LLC's Arcturus Therapeutics position peaked at $934K in Q1 2021.
139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on CSS LLC's 13F filing for Q2 2021, filed 16 Aug 2021.